Noxopharm Ltd
NOX
Company Profile
Business description
Noxopharm Ltd is an Australian clinical-stage drug development company focused on discovering and developing novel treatments for cancer and inflammation, as well as improving mRNA vaccines, based on two preclinical platforms. It is engaged in one segment which is the clinical development in the field of both oncology and non-oncology in the pan-pacific region.
Contact
60 Linksley Avenue
GlenhavenNSW2156
AUSSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
17
Stocks News & Analysis
stocks
Corning’s AI fiber boom is real, but its stock price may be getting out of hand
Corning’s optical fiber business is thriving, and the Meta deal derisks its supply buildout, but success isn’t guaranteed.
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.
stocks
ASX energy share remains cheap despite strong outlook
Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,937.20 | 12.20 | -0.14% |
| CAC 40 | 8,141.92 | 15.90 | -0.19% |
| DAX 40 | 24,083.53 | 45.45 | -0.19% |
| Dow JONES (US) | 49,167.79 | 62.92 | -0.13% |
| FTSE 100 | 10,321.09 | 57.99 | -0.56% |
| HKSE | 25,755.72 | 169.93 | -0.66% |
| NASDAQ | 24,887.10 | 50.50 | 0.20% |
| Nikkei 225 | 60,238.21 | 299.15 | -0.49% |
| NZX 50 Index | 12,766.99 | 107.95 | -0.84% |
| S&P 500 | 7,173.91 | 8.83 | 0.12% |
| S&P/ASX 200 | 8,712.40 | 8.80 | -0.10% |
| SSE Composite Index | 4,076.91 | 9.43 | -0.23% |